Integrative Network Biology Analysis of GSE6011 Uncovers Molecular Signatures in Duchenne Muscular Dystrophy

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 14 | 03 | Page :
    By

    Shashikala,

  • Vibha Rani,

  • Shazia Haider,

  1. , Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Sec-62, Uttar Pradesh, India
  2. , 1Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Sec-62, Uttar Pradesh, India
  3. Student, Department of Biosciences, Faculty of Life Sciences, Jamia Millia Islamia, New Delhi, , India

Abstract

Duchenne muscular dystrophy (DMD) is a rare, severe neuromuscular disorder demonstrated by progressive skeletal muscle deterioration and premature mortality. Despite advances in supportive care, no definitive cure exists, highlighting the need to explore novel molecular targets. The current study aimed to uncover key dysregulated genes and molecular pathways in DMD through a dataset-specific network biology approach. Publicly available microarray data (GSE6011) from DMD quadriceps muscle biopsies of 22 patients and 14 age-matched healthy controls were analyzed using GEO2R to identify differentially expressed genes (DEGs) using an adjusted p-value 0.5. The Protein–protein interaction (PPI) network was constructed via STRING and analyzed in Cytoscape, with hub genes identified using the Maximal Clique Centrality method in cytoHubba. Functional and pathway enrichment analyses were explored using Enrichr. A total of 159 DEGs were identified, including 19 genes that were found to be overregulated and 140 were downregulated. The PPI network revealed highly connected hub genes. Downregulated hubs included COL1A1, COL3A1, COL1A2, POSTN, LUM, COL6A3, SPARC, FBN1, COL5A2, and COL5A1, enriched in extracellular matrix organization, collagen fibril assembly, and fibrosis-related pathways. Upregulated hubs LPIN1, LPL, and UCP3 were linked to fatty acid metabolism, mitochondrial function, and oxidative stress regulation. These expression patterns suggest late-stage ECM remodeling with a concurrent metabolic shift in dystrophic muscle. Furthermore, molecular docking was performed to evaluate the binding interactions of FDA-approved DMD drugs (Amondys 45, Emflaza, and Vyondys 53) with the upregulated hub protein LPL, revealing favorable binding affinities and potential therapeutic relevance. This network biology and docking analysis highlights ECM remodeling and metabolic regulators as key components of DMD pathology, offering potential biomarkers and therapeutic targets.

Keywords: Network biology, Duchenne muscular dystrophy (DMD), differentially expressed genes (DEGs), neuromuscular disorder, protein–protein interaction (PPI), molecular docking

How to cite this article:
Shashikala, Vibha Rani, Shazia Haider. Integrative Network Biology Analysis of GSE6011 Uncovers Molecular Signatures in Duchenne Muscular Dystrophy. Research and Reviews : Journal of Computational Biology. 2025; 14(03):-.
How to cite this URL:
Shashikala, Vibha Rani, Shazia Haider. Integrative Network Biology Analysis of GSE6011 Uncovers Molecular Signatures in Duchenne Muscular Dystrophy. Research and Reviews : Journal of Computational Biology. 2025; 14(03):-. Available from: https://journals.stmjournals.com/rrjocb/article=2025/view=229324


References

  1. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251–267. doi: 10.1016/S1474–4422(18)30024–3.
  2. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):141. doi: 10.1186/s13023-020-01430–8.
  3. Thapa S. Vascular therapy for Duchenne muscular dystrophy (DMD). 2023;(3).
  4. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell. 1987;51(6):919–928. doi: 10.1016/0092–8674(87)90579–4.
  5. Darras BT, Menache-Starobinski CC, Hinton V, Kunkel LM. Dystrophinopathies. 2nd ed. Elsevier Inc.; 2015. doi: 10.1016/B978-0-12–417044-5.00030–5.
  6. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93. doi: 10.1016/S1474–4422(09)70271–6.
  7. Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15(7):373–386. doi: 10.1038/s41582-019-0203-3.
  8. Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105. doi: 10.1038/ncomms16105.
  9. Xin C, Wu H, Wu X, Liu Z, Luo J, Li H, et al. Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice. Hum Mol Genet. 2021;30(14):1349–1359. doi: 10.1093/hmg/ddab120.
  • PTC Therapeutics. EMFLAZA (deflazacort) – Prescribing Information. New Jersey; 2024. Available at fda.gov/medwatch
  1. Shimizu-Motohashi Y, Murakami T, Kimura E, Komaki H, Watanabe N. Exon skipping for Duchenne muscular dystrophy: A systematic review and meta-analysis. Orphanet J Rare Dis. 2018;13(1):93. doi: 10.1186/s13023-018-0834-2.
  2. Zitnik M, Leskovec J, Barabási A-L. Current and future directions in network biology. Bioinform Adv. 2024 ;4(1):vbae099. doi: 10.1093/bioadv/vbae099.
  3. Agu PC, Oseghale OU, Okoro UC, Oladipupo AR, Chukwuemeka PA, Enogieru AB, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep. 2023;13(1):21245. doi: 10.1038/s41598-023-40160-2.
  4. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: Archive for functional genomics data sets – Update. Nucleic Acids Res. 2013;41(D1):D991–D995. doi: 10.1093/nar/gks1193.
  5. Pescatori M, Broccolini A, Minetti C, Bertini E, Bruno C, D’Amico A, et al. Gene expression profiling in the early phases of DMD: A constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J. 2007;21(4):1210–1226. doi: 10.1096/fj.06-7285com.
  6. Milad N, White Z, Tehrani AY, Sellers S, Rossi FMV, Bernatchez P. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy. Skelet Muscle. 2017;7(1):19. doi: 10.1186/s13395-017-0135-9.
  7. Lombardo SD, Prezzavento O, Caraci F, Ciurleo R, Bella R, Iannuzzo G, et al. A network medicine approach for drug repurposing in Duchenne muscular dystrophy. Genes (Basel). 2021;12(4):543. doi: 10.3390/genes12040543.
  8. Wei Y, Su Q, Li X. Identification of hub genes related to Duchenne muscular dystrophy by weighted gene co-expression network analysis. Medicine (Baltimore). 2022;101(52):e32603. doi: 10.1097/MD.0000000000032603.
  9. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–D646. doi: 10.1093/nar/gkac1000.
  10. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11. doi: 10.1186/1752-0509-8-S4-S11.
  11. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90–W97. doi: 10.1093/nar/gkw377.
  12. Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44(D1):D1202–D1213. doi: 10.1093/nar/gkv951.
  13. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An Open chemical toolbox. J Cheminform. 2011;3:33. doi: 10.1186/1758-2946-3-33.
  14. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015;1263:243–250. doi: 10.1007/978-1-4939-2269-7_19.
  15. Barabási AL, Oltvai ZN. Network biology: Understanding the cell’s functional organization. Nat Rev Genet. 2004;5(2):101–113. doi: 10.1038/nrg1272.
  16. Ieronimakis N, Hays A, Prasad A, Janebodin K, Duffield JS, Reyes M. PDGFRα signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy. J Pathol. 2016;240(4):410–424. doi: 10.1002/path.4801.
  17. Serrano AL, Muñoz-Cánoves P. Fibrosis development in early-onset muscular dystrophies: Mechanisms and translational implications. Semin Cell Dev Biol. 2017;64:181–190. doi: 10.1016/j.semcdb.2016.09.013.
  18. González-González L, Alonso J. Periostin: A matricellular protein with multiple functions in cancer development and progression. Front Oncol. 2018;8:225. doi: 10.3389/fonc.2018.00225.
  19. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, Lamantia C, Carroll H. Lumican regulates collagen fibril assembly: Skin fragility and corneal opacity in the absence of lumican. J Cell Biol. 1998;141(5):1277–1286. Available at http://www.jcb.org [Accessed on September 2025].
  20. Bradshaw AD. Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol. 2012;44(3):480–488. doi: 10.1016/j.biocel.2011.12.021.
  21. Ramirez F, Pereira L. The fibrillins. Int J Biochem Cell Biol. 1999;31(2):255–259. doi: 1016/S1357–2725(98)00109–5.
  22. Donkor J, Sariahmetoglu M, Dewald J, Brindley DN, Reue K. Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J Biol Chem. 2007;282(6):3450–3457. doi: 10.1074/jbc.M610745200.
  23. Boss O, Hagen T, Lowell BB. Uncoupling proteins 2 and 3: potential regulators of mitochondrial energy metabolism. Diabetes. 2000;49(2):143–156. doi: 10.2337/diabetes.49.2.143.
  24. White Z, Terrill J, Grounds M, Arthur P, Newman J, Chen D, et al. High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia. J Clin Lipidol. 2020;14(4):459–469.e0. doi: 10.1016/j.jacl.2020.05.098.
  25. Geldenhuys WJ, Leeper TC, Carroll RT, Ouyang X, Sanford JA, Brautigam CA, et al. Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator. Bioorg Med Chem Lett. 2017;27(2):303–308. doi: 10.1016/j.bmcl.2016.11.053.
Ahead of Print Subscription Original Research
Volume 14
03
Received 23/08/2025
Accepted 19/09/2025
Published 15/10/2025
Publication Time 53 Days
130

Login


My IP

PlumX Metrics